Specialty Pharmacy

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

It will likely take decades to determine the long-term effects of cannabis, according to a session presented at the American College of Rheumatology Annual Meeting.

Top news of the day from across the healthcare landscape.

Nucala is an interleukin-5 antagonist under consideration as an add-on maintenance therapy for certain patients with chronic obstructive pulmonary disease.

Biosimilars have yet to make a significant impact on the prescription drug market.

FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Mortality related to liver cirrhosis outpaces the rate for lung, colorectal, stomach, liver, and breast cancers.

Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.

Top news of the day from across the healthcare landscape.

Major adverse cardiovascular event rates for baricitinib stabilize over time.

Exercise found to be one of the most important approaches for self-managing the consequences of multiple sclerosis.

Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer.

Sheena Babin, PharmD, business development and clinical pharmacy manager at Ochsner Health System, discusses promising specialty drugs to watch out for in the pipeline.

Amazon entering pharmacy may transform pharmacy benefit managers.

Only 1% of women aged 20 to 68 years had an oral HPV infection.

Officials with the FDA have extended the approval of vemurafenib (Zelboraf, Genentech) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare blood cancer, making it the first approved treatment for ECD.

Some patients with rheumatoid arthritis require a refined treat-to-target plan.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Top news of the day from across the healthcare landscape.

Flares and immune-related adverse events are common among patients with rheumatologic diseases but can often be successfully managed.

Study finds improved mental health resources and non-pharmacologic treatment options may be effective in reducing reduce opioid exposure among children with juvenile fibromyalgia syndrome.

Patients with active psoriatic arthritis experience significant work instability based on disease activity.

Study finds high unmet need among patients with uncontrolled gout.

Biomarker identification may improve abatacept (Orencia) treatment for rheumatoid arthritis.

A look at last week's top stories in the world of pharmacy.